Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 15

399P - Treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States

Date

14 Sep 2024

Session

Poster session 15

Topics

Tumour Site

Breast Cancer

Presenters

Shanu Modi

Citation

Annals of Oncology (2024) 35 (suppl_2): S357-S405. 10.1016/annonc/annonc1579

Authors

S. Modi1, D. Byng2, S. Zhang3, Y. Xiong4, S. Hunter5, A. Struebing2, K. Dunton6, Z. Mbanya7, W. Jacot8

Author affiliations

  • 1 Department Of Medicine, Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 2 Global Oncology Value Access & Pricing, Daiichi Sankyo Europe GmbH, 81379 - Munich/DE
  • 3 Global Oncology Value Access And Pricing, Daiichi Sankyo, Inc., 07920-2311 - Basking Ridge/US
  • 4 Data Intelligence, Center Of Excellence, Daiichi Sankyo, Inc., 07920 - Basking Ridge/US
  • 5 Data Intelligence, Center Of Excellence, Daiichi Sankyo, Inc., 07920-2311 - Basking Ridge/US
  • 6 Global Oncology Value Access & Pricing, Daiichi Sankyo UK Ltd, UB8 1DH - Uxbridge/GB
  • 7 Market Access, AstraZeneca, CB2 0AA - Cambridge/GB
  • 8 Department Of Medical Oncology, Institut du Cancer de Montpellier, 34298 - Montpellier/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 399P

Background

Over half of human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancers (mBC) are now recognized as HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+ and in situ hybridization [ISH−]). DESTINY-Breast06 (NCT04494425) is assessing if trastuzumab deruxtecan (T-DXd) can replace a first line of metastatic chemotherapy following endocrine therapy (ET) in hormone receptor positive (HR+), HER2-low patients (pts). We report results from an observational, retrospective analysis used to understand the characteristics and outcomes of a real-world (rw) United States cohort of HR+, HER2-low mBC pts who initiated a chemotherapy-based line of therapy (LOT) in the mBC setting.

Methods

The analysis used the nationwide Flatiron Health electronic health record-derived de-identified database (01/01/2011–08/31/2023). Eligible HR+, HER2-low pts initiated chemotherapy (index LOT) after ≥2L ET or ≤6 months (m) of 1L ET + cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) in the mBC setting. This cohort met additional inclusion/exclusion criteria similar to the DB-06 trial. Rw overall survival (rwOS), time to treatment discontinuation or death (rwTTD/D), and time to next treatment or death (rwTTNT/D) from start of the index LOT (index date) were assessed using Kaplan-Meier analysis with corresponding 95% confidence intervals (CI).

Results

At index date, median age of final cohort (N=963) was 64 years; 271 (28.1%) were categorized as de novo stage IV. 131 (13.6%) pts received second line chemotherapy (index LOT) within 6m of initiating first line treatment with ET+CDK4/6i; 832 (86.4%) pts received chemotherapy after two or more prior lines of ET. The most common chemotherapy (index LOT) was capecitabine (45.2%). From index date, median rwOS was 18.7m (95% CI: 17.3–20.2), median rwTTD/D was 4.9m (95% CI: 4.6–5.2) and median rwTTNT/D was 5.6m (95% CI: 5.3–6.0).

Conclusions

This study provides insight into the clinical characteristics and outcomes of a large rw cohort of HR+, HER2-low pts initiating chemotherapy following ET in the mBC setting. The findings underscore the poor disease prognosis and limited efficacy of chemotherapy-based regimens for pts who have progressed on ET regimens.

Clinical trial identification

Editorial acknowledgement

Medical writing support was provided by Lillian Dukes and Marielle Brown of Costello Medical (Boston MA, USA) and funded by Daiichi Sankyo.

Legal entity responsible for the study

Daiichi Sankyo.

Funding

Daiichi Sankyo, AstraZeneca.

Disclosure

S. Modi: Financial Interests, Institutional, Research Grant: AstraZeneca, Daiichi Sankyo, Duality Bio, Genentech, Nuvation, Seagen; Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Daiichi Sankyo, Duality Bio, Eli Lilly, Genentech, Gilead, GSK, Macrogenics, Seagen; Financial Interests, Personal, Other, Support for attending meetings and/or travel: AstraZeneca, Daiichi Sankyo, Seagen. D. Byng: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo Europe GmbH. S. Zhang: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo, Inc. Y. Xiong: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo, Inc. S. Hunter: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo, Inc. A. Struebing: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo Europe, GmbH. K. Dunton: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo UK Ltd. Z. Mbanya: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. W. Jacot: Financial Interests, Institutional, Research Grant: AstraZeneca, Daiichi Sankyo; Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, BMS, Daiichi Sankyo, Eisai, Lilly (France), MSD, Novartis, Pfizer, Roche, Seagen; Financial Interests, Personal, Other, Support for attending meetings and/or travel: AstraZeneca, Chugai, Eisai, GSK, Lilly (France), Novartis, Pfizer, Pierre Fabre, Roche, Sanofi Aventis; Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, Daiichi Sankyo, Eisai, Gilead, Lilly (France), MSD, Novartis, Pfizer, Roche, Seagen.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.

  • Analytics cookies help us improve our website by collecting and reporting information on its usage.

  • We use marketing cookies to build a profile of you as a user through your actions on our site in order to better understand your interests and provide you with pertinent suggestions.